Results 51 to 60 of about 7,837 (201)
HEMOPHILIA INHIBITOR PATIENTS: THE USE OF RECOMBINANT FACTOR VIIa
Zdravniški Vestnik, 2004 Background. Recombinant factor VIIa can induce hemostasis and controls bleeding in surgery in hemophilia inhibitor patients and in other hemostatic disorders, e.g.
Dušan Andoljšek, Samo Zver
doaj
Characterizing the Healthcare Utilization and Costs of Hereditary Hemorrhagic Telangiectasia
American Journal of Hematology, Volume 100, Issue 10, Page 1722-1735, October 2025.ABSTRACT Hereditary hemorrhagic telangiectasia (HHT) is the second‐most common inherited bleeding disorder worldwide, afflicting one in 4000–5000 people, and is the most morbid inherited bleeding disorder of women. HHT causes recurrent severe epistaxis, chronic gastrointestinal bleeding, heavy menstrual bleeding, and arteriovenous malformations in the ...
Hanny Al‐Samkari +5 more
wiley +1 more source
Optimal use of recombinant factor VIIa in the control of bleeding episodes in hemophilic patients
Drug Design, Development and Therapy, 2010 John PuetzSaint Louis University, Department of Pediatrics, St Louis, Missouri, USAAbstract: One of the last remaining clinical hurdles in the treatment of people with hemophilia is the development of inhibitors. Alloantibodies or autoantibodies directed
John Puetz
doaj
Iatreia, 2018 Introduction and objectives: Patients diagnosed with severe hemophilia are at risk of developing inhibitors of low or high title, being the treatment of choice for this latter group of patients the immune tolerance therapy (ITI).
Casas, Claudia Patricia +5 more
doaj +1 more source
MedComm, Volume 6, Issue 10, October 2025.Intracerebral hemorrhage (ICH) causes complex pathophysiological mechanisms such as primary injury and secondary injury, leading to neuronal damage. The emerging treatment strategies can carry out precise treatment at different time stages after ICH, and have offer enhanced targeting, intelligence, and efficiency.
Haojie Zhang +3 more
wiley +1 more source
Complications at Diagnosis of Pediatric Chronic Myeloid Leukemia in Chronic Phase
Pediatric Blood &Cancer, Volume 72, Issue 10, October 2025.ABSTRACT Chronic myeloid leukemia (CML) is uncommon during the first two decades of life, resulting in limited experience of pediatricians in handling this leukemia. This is even more true when it comes to managing rare complications at the time of diagnosis.
Nirmalya Roy Moulik +4 more
wiley +1 more source
Physiological Reports, Volume 13, Issue 19, October 2025.Abstract In the present study, we aimed at elucidating whether exposure to chronic stress affects the expression of cardiac mineralocorticoid receptors (MRs), whether it influences cardiac structure and function, and whether MRs blockade attenuates the stress‐induced changes.
D. Sztechman +4 more
wiley +1 more source
Case Reports in Gastroenterology, 2009 Recombinant activated coagulation factor VII (rFVIIa) is known to be effective in the management of acquired deficiencies of factor VII and platelet function defects.
Ju-Hee Lee +12 more
doaj +1 more source
The FASEB Journal, Volume 39, Issue 17, 15 September 2025.The study involved patients who experienced acute kidney injury (AKI) following liver transplantation at the Third Affiliated Hospital of Sun Yat‐sen University from January 2015 to February 2023. Patients were categorized into CKD and non‐CKD groups based on their progression to chronic kidney disease (CKD) 3 months post‐surgery.
Liping Li +9 more
wiley +1 more source
Overview of the use of recombinant factor VIIa in children
Pediatric Health, Medicine and Therapeutics, 2014 John Puetz Department of Pediatrics, Division of Hematology/Oncology, Cardinal Glennon Children's Medical Center, Saint Louis University, St Louis, MO, USA Abstract: Recombinant factor VIIa (rFVIIa) was initially developed as a bypassing agent to ...
Puetz J
doaj